跳至主要内容
临床试验/NCT04099771
NCT04099771Unknown早期 1 期

Low Dose Ketamine for Acute Management of Mood Disorders With Suicidal Ideation

The Miriam Hospital1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2019年7月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
入组人数
20
试验地点
1
主要终点
Completion of total infusion of ketamine by participants

研究概览

简要总结

This study will explore whether the use of a medication, Ketamine, can help patients who come to the ER with thoughts of suicide by improving their mood and reducing thoughts of suicide. Ketamine has been used for this purpose in patients who have been hospitalized, but it has not been well studied in the ER. The investigators are first trying to show that patients and doctors in the ER find the treatment acceptable. The investigators also hope to determine whether Ketamine is effective in decreasing the severity of patient's suicidal thinking while in the ER. If this treatment works, future studies will look at whether it can help patients be discharged from the hospital earlier.

Research Procedures: Patients will be enrolled into the study on a voluntary basis after the research assistant has fully explained all the risks and benefits of the study (informed consent). Research assistants, Emergency Department staff, and the Psychiatry team will help identify patients for the study. Patients will be asked to complete surveys measuring the degree of their suicidal thinking and mood. Additional information will be collected on patients such as their demographics, current medications, and medical problems. Patients in the study will receive the medication, Ketamine, which will be given through an intravenous catheter (IV) at a dose based on the patient's weight and slowly infused over 40 minutes. Patients will be monitored during their stay in the Emergency Department by Emergency Department physicians and nurses for any signs of side effects to the medication. Patients will be asked to complete several surveys at specific time periods after the administration of Ketamine. All patients in the study will receive usual psychiatric care in addition to the study medication.

详细描述

Mood disorders complicated by suicidal ideation (SI) are common among patients presenting to the Emergency Department (ED). Under current standard practice, patients awaiting psychiatric evaluation in the emergency department do not typically receive interventions to address their mood disorder or SI. With no end to the extended ED boarding of psychiatric patients in sight, improvements in the acute treatment of SI with ketamine may help more patients receive prompt and appropriate treatment. Low-dose ketamine has been well studied in psychiatric literature. Studies involving a single dose of ketamine are promising, demonstrating both immediate and sustained reductions in suicidal ideations. Low dose ketamine has been well-studied in the ED for pain, asthma, and agitation, but not mood disorders or SI.

This study aims to determine whether or not it is feasible to administer low dose ketamine in the emergency department for the management of mood disorders with SI. Feasibility of ketamine administration in the ED and will be determined by: (1) ability to recruit participants, (2) tolerability of the intervention, and (3) acceptability by patients/providers. The investigators will also explore whether the administration of ketamine results in improvements in mood and SI.

This prospective open label feasibility pilot study will enroll 20 participants to receive ketamine at 0.5mg/kg infused intravenously over 40 minutes. Patients that have active suicidal ideation as determined by psychiatry staff who are being admitted to psychiatry under voluntary certification will be eligible for the study. The investigators will assess self-reported mood and suicidal ideations pre- and post-infusion of ketamine. Participants will complete assessments at baseline (pre-infusion), 2 hours and 6 hours post-infusion, and daily while in the ED until inpatient disposition.

The investigators hypothesize ketamine administration will be feasible in the emergency department and will result in improved mood and decreased SI.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • English speaking
  • between 18 and 65 years of age
  • have active suicidal ideation as determined by psychiatry staff
  • are being admitted to psychiatry under voluntary certification and are able to provide informed consent.

排除标准

  • have been previously enrolled in the trial
  • are pregnant or breastfeeding; have a known or suspected allergy to ketamine; have used ketamine within 24h of presentation
  • require antipsychotics (prescription or PRN by ED staff) or ED administration of other mood-altering medications for the management of acute agitation
  • have known renal or liver failure; have neurologic, respiratory, or hemodynamic compromise as determined by the treating ED physician
  • have history of stroke or cardiac disease (prior MI, cardiac stents or bypass surgery); or are incarcerated

研究组 & 干预措施

Ketamine

Experimental

A total of 20 patients identified as having suicidal ideation will receive ketamine at 0.5mg/kg infused intravenously over 40 minutes.

干预措施: Ketamine (Drug)

结局指标

主要结局

Completion of total infusion of ketamine by participants

时间窗: One year

The study will be considered feasible if the intervention is tolerable to participants with no more than 25% of enrolled participants stopping the infusion of ketamine because of side effects (i.e., early stopping).

Number and Rate of Participants Recruited into the Study throughout study period

时间窗: One year

The study will be considered feasible if the investigators are able to successfully enroll twenty participants into the study over a one year period (\~1 - 2 participants per month).

Percentage of participants and providers with positive response to ketamine administration

时间窗: One year

The study will be considered feasible if the intervention is considered acceptable to patients and providers (75% positive response on acceptability questionnaires).

次要结局

  • Reduction of SI in mood disorders by ketamine(30 days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Ketamine for Mood Disorders With Suicidal Ideation | 临床试验